MA26678A1 - Forme polymorphe de monohydrate de zopolrestat, procedes pour sa preparation et compositions pharmaceutiques la contenant - Google Patents

Forme polymorphe de monohydrate de zopolrestat, procedes pour sa preparation et compositions pharmaceutiques la contenant

Info

Publication number
MA26678A1
MA26678A1 MA25738A MA25738A MA26678A1 MA 26678 A1 MA26678 A1 MA 26678A1 MA 25738 A MA25738 A MA 25738A MA 25738 A MA25738 A MA 25738A MA 26678 A1 MA26678 A1 MA 26678A1
Authority
MA
Morocco
Prior art keywords
preparation
methods
pharmaceutical compositions
same
compositions containing
Prior art date
Application number
MA25738A
Other languages
English (en)
Inventor
Francis Lambert John
Norris Timothy
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26678A1 publication Critical patent/MA26678A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
MA25738A 1998-08-21 1999-08-18 Forme polymorphe de monohydrate de zopolrestat, procedes pour sa preparation et compositions pharmaceutiques la contenant MA26678A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9747498P 1998-08-21 1998-08-21

Publications (1)

Publication Number Publication Date
MA26678A1 true MA26678A1 (fr) 2004-12-20

Family

ID=22263562

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25738A MA26678A1 (fr) 1998-08-21 1999-08-18 Forme polymorphe de monohydrate de zopolrestat, procedes pour sa preparation et compositions pharmaceutiques la contenant

Country Status (31)

Country Link
US (1) US6159976A (fr)
EP (1) EP0982306A3 (fr)
JP (1) JP2000072769A (fr)
KR (1) KR20000017411A (fr)
CN (1) CN1245804A (fr)
AP (1) AP9901662A0 (fr)
AU (1) AU4453299A (fr)
BG (1) BG103674A (fr)
BR (1) BR9903873A (fr)
CA (1) CA2280590A1 (fr)
EA (1) EA199900675A3 (fr)
EE (1) EE9900385A (fr)
GT (1) GT199900137A (fr)
HR (1) HRP990259A2 (fr)
HU (1) HUP9902783A3 (fr)
ID (1) ID23307A (fr)
IL (1) IL131419A0 (fr)
IS (1) IS5155A (fr)
MA (1) MA26678A1 (fr)
NO (1) NO994027L (fr)
NZ (1) NZ337363A (fr)
OA (1) OA11150A (fr)
PA (1) PA8480601A1 (fr)
PE (1) PE20000993A1 (fr)
PL (1) PL335016A1 (fr)
SG (1) SG83147A1 (fr)
TN (1) TNSN99159A1 (fr)
TR (1) TR199901996A2 (fr)
UY (1) UY25668A1 (fr)
YU (1) YU39899A (fr)
ZA (1) ZA995297B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221430T1 (hr) 2010-07-16 2023-01-06 The Trustees Of Columbia University In The City Of New York Inhibitori aldozoreduktaze i njihova uporaba
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
WO2014126885A1 (fr) * 2013-02-13 2014-08-21 Mylari Banavara L Sels solubles dans l'eau d'inhibiteurs d'aldose réductase pour le traitement de complications diabétiques
RS61239B1 (sr) 2016-06-21 2021-01-29 Univ Columbia Inhibitori aldozne reduktaze i postupci korišćenja
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CA3132136A1 (fr) 2019-04-01 2020-10-08 Andrew Wasmuth Inhibiteurs de l'aldose reductase
JP2022531466A (ja) 2019-05-07 2022-07-06 ユニバーシティ オブ マイアミ 遺伝性ニューロパチーおよび関連障害の処置および検出
EP4125909A1 (fr) 2020-03-31 2023-02-08 Applied Therapeutics Inc. Inhibiteurs d'aldose réductase pour le traitement du syndrome de détresse respiratoire aiguë, d'une inflammation/lésion pulmonaire aiguë, d'une lésion cardiaque et pour une thérapie antivirale
WO2021222165A1 (fr) 2020-05-01 2021-11-04 Applied Therapeutics, Inc. Inhibiteurs d'aldose réductase pour le traitement d'une déficience en sorbitol déshydrogénase
US20230322786A1 (en) * 2020-09-08 2023-10-12 Teva Pharmaceuticals International Gmbh Solid state forms of at-001 and process for preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748280A (en) * 1985-11-07 1988-05-31 Pfizer Inc. Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6)
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US4904782A (en) * 1988-02-29 1990-02-27 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
WO1992003432A1 (fr) * 1990-08-28 1992-03-05 Pfizer Inc. Monohydrate d'acide 3-(5-trifluoromethylbenzothiazol-2-ylmethyle)-4-oxo-3h-phytalazine-1-ylacetique
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
IL120264A0 (en) * 1996-02-29 1997-06-10 Pfizer Method of reducing tissue damage associated with non-cardiac ischemia

Also Published As

Publication number Publication date
YU39899A (sh) 2002-12-10
BG103674A (en) 2000-03-31
EP0982306A3 (fr) 2000-07-05
US6159976A (en) 2000-12-12
EA199900675A2 (ru) 2000-02-28
ZA995297B (en) 2001-02-19
PA8480601A1 (es) 2000-09-29
AU4453299A (en) 2000-03-09
NZ337363A (en) 2001-01-26
NO994027L (no) 2000-02-22
SG83147A1 (en) 2001-09-18
EP0982306A2 (fr) 2000-03-01
HUP9902783A2 (hu) 2000-12-28
AP9901662A0 (en) 1999-09-30
CA2280590A1 (fr) 2000-02-21
BR9903873A (pt) 2000-09-19
PE20000993A1 (es) 2000-10-04
NO994027D0 (no) 1999-08-20
HUP9902783A3 (en) 2001-01-29
ID23307A (id) 2000-04-05
HU9902783D0 (en) 1999-10-28
TNSN99159A1 (fr) 2005-11-10
IS5155A (is) 2000-02-22
EA199900675A3 (ru) 2000-06-26
TR199901996A2 (xx) 2000-03-21
EE9900385A (et) 2000-04-17
UY25668A1 (es) 2001-08-27
CN1245804A (zh) 2000-03-01
GT199900137A (es) 2001-02-09
PL335016A1 (en) 2000-02-28
HRP990259A2 (en) 2000-06-30
JP2000072769A (ja) 2000-03-07
IL131419A0 (en) 2001-01-28
OA11150A (en) 2003-04-16
KR20000017411A (ko) 2000-03-25

Similar Documents

Publication Publication Date Title
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26654A1 (fr) Pyrrolopyrimidines nouvelles procede pour leur preparation et compositions pharmaceutiques les contenant
FR2780728B1 (fr) Sel de paroxetine nouveau, procede pour sa preparation et compositions pharmaceutiques le contenant
MA26622A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
EE04613B1 (et) Sahhariidijääkidega asendatud 1,4-bensotiasepiin-1,1-dioksiidi derivaadid, meetod nende valmistamiseks, ühendite kasutamine ning neid sisaldav ravim
IS5317A (is) Föst lyfjasamsetning sem inniheldur bensófúran afleiður
PT1066027E (pt) Composicao farmaceutica de topiramato
MA26415A1 (fr) Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant
FR2831883B1 (fr) Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
DK1052974T3 (da) Farmaceutisk sammensætning indeholdende epothilon
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26559A1 (fr) Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
HUP0103913A3 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
MA26686A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26653A1 (fr) Pyrrolo [2,3- d] pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26526A1 (fr) Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant.
IS5747A (is) Oxazólidínón afleiður, aðferð fyrir framleiðslu þeirra og lyfjasamsetninga sem innihalda þær
MA26443A1 (fr) Aralkyl- et aralkylidene-lactames et -imides heterocycliques, procedes pour leur preparation et compositions pharmaceutiques les contenant
EE200100529A (et) Diabeedivastase agensi uudsed polümorfsed vormid:nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
MA26433A1 (fr) Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26499A1 (fr) Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .
MA26490A1 (fr) Derives de tetrahydroisoquinoleine nouveaux, procedes pour leur preparation et compositions pharmaceutiques les contenant.
HUP0204157A3 (en) 1,3-dihydro-2h-indol-2-one derivatives, process for preparation of the compounds and pharmaceutical compositions containing the same
MA26624A1 (fr) Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant